Home › ARCA Biopharma Announces Health Canada Acceptance Of Genetic-AF Clinical Trial Application
 

Keywords :   


ARCA Biopharma Announces Health Canada Acceptance Of Genetic-AF Clinical Trial Application

2014-09-03 11:53:10| drugdiscoveryonline Home Page

ARCA biopharma, Inc. a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, recently announced that the Company’s Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada

Tags: health canada application trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.10GEW promotes Billy Adams to VP of operations
08.10Constantia Flexibles earns Letter of Compatibility from RecyClass
08.10Saalt Adds Teen Line
08.10Wise acquires continuous and unit set business forms assets of Victor Printing
08.10Hurricane Milton Public Advisory Number 14A
08.10Summary for Hurricane Milton (AT4/AL142024)
08.10Atlantic Tropical Weather Outlook
08.10Eastern North Pacific Tropical Weather Outlook
More »